Dapsone

Aczone (dapsone) is a small molecule pharmaceutical. Dapsone was first approved as Aczone on 2005-07-07. It is used to treat aids-related opportunistic infections, dermatitis herpetiformis, lepromatous leprosy, and relapsing polychondritis in the USA. It is known to target hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase. Dapsone's patent is valid until 2033-11-18 (FDA).